AstraZeneca Inks $815M Deal To Develop Anemia Drug

Law360, New York (July 31, 2013, 2:19 PM EDT) -- British drug giant AstraZeneca LP has agreed to pay up to $815 million for the rights to an anemia treatment by San Francisco-based FibroGen Inc., which will be commercialized in markets including the U.S. and China, the firms said Wednesday. 

Under the terms of the deal, AstraZeneca will first pay FibroGen $350 million, and then follow up with milestone payments potentially up to $465 million, according to a joint statement by the firms. The deal also allows for additional payments tied to further sales-related milestones, the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.